Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Date:8/22/2007

SOMERSET, N.J., Aug. 22 /PRNewswire-FirstCall/ - Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in the International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669) reports that ONCONASE(R) substantially decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer agents.

The pre-clinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with ONCONASE reduced intracellular oxidative stress by suppressing ROI generation and promoting their degradation. The anti-oxidative function of ONCONASE may be an important element of its antiproliferative/cytotoxic activity towards cancer cells and a possible mechanism of its well-documented synergism with other anti-cancer agents. Additionally, the data indicate that ONCONASE has a propensity to reverse the generation of ROI from asbestos exposure in mesothelial cells. The Company is currently conducting a Phase IIIb human clinical trial of ONCONASE for the treatment of patients suffering from unresectable malignant mesothelioma.

"The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "ONCONASE's therapeutic potential is broad. This study shows that ONCONASE has potential not only for cancer, but for conditions pathogenetically related to oxidative stress or the activation of NF-kappa B, such as inflammation, autoimmune diseases, atherosclerosis and septic shock."

About ONCONASE(R)
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...N, Mass., Nov. 6 DUSA Ph...ermatology company that is developing and marketin...ther products focused on patients with common skin...nd Chief Executive Officer, will present a corpora...ummit 2009 on Tuesday, November 10, 2009 at 10:00 ...
(Date:11/6/2009)...Calif., Nov. 6 Kaiser Foundation H...P/H), and their subsidiaries reported today a comb...the quarter ended September 30, 2009, compared to ...perating income in the third quarter was $336 mill... of last year. Net non-operating income was $233 m...
(Date:11/6/2009)...Nov. 6 Caraco Pharmaceut...nched ketorolac tromethamine ophthalmic solution, ...nd Drug Administration (FDA) for Sun Pharma,s Abbr...ular® ophthalmic solution on the first day fo...lac is therapeutically equivalent to Acular® ...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 1Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 3Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 4Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 1Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 2Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 3Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 1Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 2Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 5
...nc., a,biopharmaceutical company engaged in the di... treatment of immune-mediated diseases, announced ...modified version of TRX1,MTRX1011A, an anti-CD4 mo...hat has begun enrolling patients. The clinical tri...th single and multiple doses of MTRX1011A.,Under t...
...ffectiveness of Autologous Therapy, DUSSELDORF, G...entative study of knee osteoarthritis, published i...itis and Cartilage", confirm,the safety and effect...matory proteins obtained from the patient,s own bl...rchers at Heinrich Heine University in Dusseldorf ...
Other Medicine Technology:Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2
(Date:11/9/2009)...hat women treated for breast cancer are at higher ...ts. Published in the December 15, 2009 issue of C...ncer Society, the study,s results indicate that br...t from additional therapies following surgery, suc... women with dense breast tissue are at increased r...
(Date:11/8/2009).... 8 Jon O,Brien, presid...statement about the passage of HR 3962: ,, "Be...oters a lot about core values. We in the prochoice... to overcome the struggles ordinary Americans have...cannot afford basic healthcare or have to choose b...
(Date:11/8/2009)...ouse Passage of Health Care Reform Bill ,, Cr...ove coverage for all Americans ,, HARRISBURG, ...UMMARY: Last night the United States House of Rep...gislation that would strengthen Medicare for senio...hat prices millions of Americans out of affordable...
(Date:11/8/2009)... take you out of the game later, doctors say , ...njuries are the talk of the NFL this season, sidel...nning back Willie Parker. , Officials at the Am...Academy of Podiatric Sports Medicine are warning a...fall sports like football and lacrosse. , "Many...
(Date:11/8/2009).... 7 Tonight the House o...e for America Act, landmark health reform legislat...quality, affordable, stable and secure health care...ome of the insurance industry,s worst practices, w...ut the deficit by $104 billion over ten years. Gro...
Breaking Medicine News(10 mins):Health News:Breast density associated with increased risk of cancer recurrence 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:Rx for Fall Foot Injuries 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3
...S doctors tend to prescribe unwanted, even possibl...ug makers in the name of lecture assignments. ...uld require drug makers to disclose payments made ...y other specialty. Not coincidentally prescri...
...ablish relationships, some physicians tell patient... travel experiences and political beliefs. Univer... investigation has found these personal disclosure... in about a third of patient visits. The disclosur...
...d the disheartening reasons behind her recent weig...ntly looking frail and emaciated in all her recent...too thin. The 'Tomb Raider' star revealed ... gone through a lot," the Daily Mail quoted Jolie,...
...y of Washington shows that the work intended for g...tate economy . The research was conducted b... geography; Amy Hagopian, professor in the School ...ration director of the Department of Global Health...
... patients with an alcohol-use disorder (AUD) are m... need it for a longer period of time. More than 3...ing intensive care per year in the United States, ...omic burden, costing a median 32,000 dollars to 56...
...iabetes, obesity and heart disease, chronic illnes... of death in poor countries by 2015. These...hich include malaria, AIDS and tuberculosis. ...tion and economy. The countries need to take up pr...
Other Medicine News:Health News:US Lawmakers Considering Legislation to Restrict Payments by Drug Companies to Doctors 2Health News:US Lawmakers Considering Legislation to Restrict Payments by Drug Companies to Doctors 3Health News:Personal Disclosure by Physician may Harm Patients 2Health News:Personal Disclosure by Physician may Harm Patients 3Health News:Personal Disclosure by Physician may Harm Patients 4Health News:Global Health Enriching the States Economy 2Health News:Patients With Alcohol Problem Need Mechanical Ventilation 2Health News:Non Communicable Diseases to Be the Cause of Deaths in Poor Countries by 2115-World Bank 2
Snap-In Snap-Out®-II Strong Grasping Forceps Insert
Maryland Dissector, dual-incision
Optima III 45 Noninsulated Maryland Dissector
Palpation Probe, dual-incision
Medicine Products: